K-P. Kim - Asan Medical Center, University of Ulsan

基本信息

浏览量：1

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 65 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

58P Efficacy and Safety of Liposomal Irinotecan (Nal-Iri) Plus Fluorouracil (5-FU) and Leucovorin (LV) Versus 5-FU/LV Alone for Advanced Biliary Tract Cancer (BTC) after Progression on Gemcitabine-Based Therapy: A Pooled Analysis of the NIFTY and NALIRICC Trials

C. Yoo,A. Saborowski,J. Hyung, P. Wenzel, I. Kim, H. Wege,K-P. Kim, G. Folprecht,B-Y. Ryoo, P. Schütt, J. Cheon,T.O. Goetze, H. Ryu, J.S. Lee, A. Vogel

Annals of Oncology (2024)

引用0浏览0引用

1014P Phase Ib Trial Results of Safety, Pharmacokinetics and Pharmacodynamics of TU2218, TGFβ-RI and VEGF-R2 Dual Inhibitor in Combination with Pembrolizumab in Patients with Advanced Solid Tumors

A.W. Tolcher, H-T. Kim, D-Y. Oh,K-P. Kim, A. Chaudhry,M. Chaney

Annals of Oncology (2024)

引用0浏览0引用

104P Final Analysis of the Prospective, Randomized Phase II STAMP Trial: Adjuvant Gemcitabine Plus Cisplatin (gemcis) Versus Capecitabine (CAP) in Node-Positive Extrahepatic Cholangiocarcinoma (CCA)

H. Jeong,K-P. Kim,J. H. Jeong,D. W. Hwang,J. H. Lee, K-H. Kim,D-B. Moon, M. A. Lee,S. J. Park, H. Chon,J-H. Park,J. S. Lee,B-Y. Ryoo,C. Yoo

Annals of Oncology (2023): S221-S221

引用0浏览0引用

97P Neoadjuvant Durvalumab Plus Gemcitabine and Cisplatin (d+gemcis) Versus Gemcis Alone for Localized Biliary Tract Cancer (BTC): Results of a Randomized, Multicenter, Open-Label, Phase II Trial (DEBATE)

C. Yoo,J. O. Park,K-P. Kim,J. Hyung,B-Y. Ryoo,J. Y. Hong,S. H. Shin,T. J. Song,D. Oh, W. Lee,B. J. Kwak,J. H. Lee,D. W. Hwang

Annals of Oncology (2023): S216-S216

引用0浏览0引用

118P Artificial Intelligence (Ai)-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes (tils) As a Predictive Biomarker for Anti-Pd-1 in Advanced Biliary Tract Cancer (BTC)

Y. Bang,C-K. Lee,K. Bang, H-D. Kim,K-P. Kim, J. H. Jeong,B-Y. Ryoo,C. Oum, S. Kim,Y. Lim,G. Park,C-Y. Ock,J. H. Shin,C. Yoo

Annals of Oncology (2023): S226-S226

引用0浏览0引用

EP11.03-38 Comparison of Real-World Outcomes in Ansclc Patients Receiving 1L Immunotherapy Alone or in Combination with Chemotherapy

S.M. Lim,H.A. Jung, D.H. Lee,S. Lim, M.J. Lee, H. Yu, S. Yoon,K-p. Kim,H. Jeong, J. Kim, X. Zhao,K.C. Toh, D. Kim

Journal of Thoracic Oncologyno. 11 (2023): S637

引用0浏览0引用

Comparison of Real-World Outcomes in aNSCLC Patients Receiving 1L Immunotherapy Alone or in Combination with Chemotherapy

S. M. Lim,H. A. Jung, D. H. Lee,S. Lim, M. J. Lee, H. Yu, S. Yoon,K-P. Kim,H. Jeong, J. Kim, X. Zhao,K. C. Toh, D. Kim

JOURNAL OF THORACIC ONCOLOGYno. 11 (2023): S637-S637

引用0浏览0引用

1043P First-in-human Study of TU2218, TGFβRI and VEGFR2 Dual Inhibitor in Patients with Advanced Solid Tumors

D-Y. Oh, E. LEE,A.W. Tolcher,K-P. Kim, H-T. Kim

Annals of Oncology (2023): S633

引用0浏览0引用

103P Individual Patient Data (IPD) Meta-Analysis of Randomised Trials to Compare Efficacy of Second-Line Fluoropyrimidine-Based Chemotherapy in Advanced Biliary Tract Cancer (BTC)

J. Hyung,M. Kang, I. Kim,P. Kim,B-Y. Ryoo,J. Cheon,H. Ryu,J. S. Lee, G. K. Abou-Alfa,J-W. Kim,I. Choi,J. H. Park,J. W. Kim,C. Yoo

Annals of Oncology（2023）

引用0浏览0引用

Phase II Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on First-Line Atezolizumab Plus Bevacizumab: REGONEXT Trial

J. Cheon,B-Y. Ryoo,H-D. Kim,K-P. Kim,M. H. Ryu,H. J. Chon,B. Kang,R. S. Finn,C. Yoo

Journal of clinical oncologyno. 4_suppl (2023): TPS634-TPS634

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn